XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jun. 30, 2020
Apr. 30, 2020
Jan. 31, 2020
Aug. 30, 2019
Oct. 31, 2018
Apr. 30, 2018
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2020
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                 $ 388,446 $ 9,154,133 $ 729,359 $ 10,137,602    
Grant funding liability                 3,806,161   3,806,161     $ 2,475,031
Advaccine | Collaborative Arrangement, Product                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Upfront payment received   $ 3,000,000             1,200,000 0 $ 3,600,000 0    
Additional revenue to be achieved   200,000,000                        
Royalty period                     10 years      
Annual maintenance fee                     $ 1,500,000      
Annual maintenance period                     5 years      
Agreement, number of days written notice before termination                     18 months      
Collaboration agreement, payment earned   $ 2,000,000                        
Revenues                         $ 5,000,000  
Advaccine | Collaborative Arrangement, Product | Revenue under collaborative research and development arrangements, including from affiliated entities                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                 0 0 $ 0 0    
ApolloBio | Collaborative Arrangement, Product                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Additional revenue to be achieved                     $ 20,000,000      
Royalty period                     10 years      
Agreement, number of days written notice before termination                     90 days      
Revenues                   0   0    
Period from effective date for termination                     1 year      
Funding received for research and development                 238,000   $ 243,000      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Collaborative agreement, funding to be received       $ 6,900,000                    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Collaborative agreement, funding to be received               $ 56,000,000            
Collaborative agreement, period to receive funding for research and development               5 years            
Funding received for research and development                 0 958,000 1,800,000 6,100,000    
Deferred grant funding, from affiliate                 1,500,000   1,500,000      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Collaborative agreement, funding to be received       5,000,000                    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Collaborative agreement, funding to be received       $ 1,300,000 $ 9,000,000                  
Funding received for research and development                 8,000 192,000 196,000 946,000    
Grant funding liability                 2,200,000   2,200,000      
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Funding received for research and development           $ 1,100,000 $ 2,200,000   0 47,000 70,000 132,000    
Grant funding liability                 87,000   87,000      
Department of Defence | Collaborative Arrangement, Product                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Contra-research and development expense                 0 0 0 6,100,000    
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Funding received for research and development     $ 54,500,000                      
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                 $ 0 $ 9,000,000 $ 0 $ 9,600,000    
Purchase price, procurement contract $ 10,700,000   $ 16,800,000